Search results
Pulmonary Hypertension
Author(s):
Brendan P Madden
Added:
3 years ago
Article
Author(s):
Victor F Tapson
Added:
3 years ago
Chronic thromboembolic pulmonary hypertension (CTEPH) results from obstruction of the major pulmonary arteries by unresolved or organized pulmonary emboli that have become incorporated into the vessel wall, ultimately causing increased pulmonary vascular resistances. Without intervention, CTEPH is a progressive, fatal disease for which there is no proven effective medical therapy. Pulmonary…
View more
Author(s):
Gurushankar Govindarajan
,
James R Sowers
,
Craig S Stump
Added:
3 years ago
There has been an increase in the prevalence of diabetes mellitus over the past 40 years, both in the US and worldwide. The worldwide prevalence of diabetes in 2000 was approximately 2.8% and is estimated to grow to 4.4% by 2030. This translates to a projected rise of diabetes from 171 million in 2000 to well over 350 million in 2030. The epidemic of diabetes will continue to rise as there is…
View more
Author(s):
Thomas Münzel
,
Mette Sørensen
Added:
3 years ago
The health burden of environmental noise has recently been quantified in a report of the World Health Organization (WHO) in terms of disabilityadjusted life years (DALYs; i.e., the number of years lost because of disability or death – a measure that combines both morbidity and mortality). The WHO estimates that – in western Europeans – each year 45,000 DALYs are lost because of noise-induced…
View more
Author(s):
Robert P Frantz
Added:
3 years ago
Pulmonary arterial hypertension (PAH) is a rare but life-threatening condition that has traditionally required treatment with continuous intravenous epoprostenol via an indwelling central catheter.1–3 Such therapy improves outcome, but is fraught with side effects, expense, and risk of catheter-related complications. Therapy of PAH has evolved tremendously in recent years, reflecting the…
View more
Author(s):
Jean-Luc Vachiéry
Added:
3 years ago
Prostacyclins in PAH - Pathobiological Rationale
Endothelial dysfunction is the cornerstone event in the pathobiology of pulmonary arterial hypertension (PAH), a rapidly evolving clinical syndrome of dyspnoea and fatigue eventually leading to right ventricular failure and death.1 In the pulmonary vascular bed, endothelial cells are the major source of mediators modulating pulmonary vascular tone…
View more
Author(s):
John G Coghlan
Added:
3 years ago
The pace of progress in the field of pulmonary arterial hypertension (PAH) continues to be breathtaking. In the past couple of years two new oral agents have been granted licences. Fourteen major international drug trials are underway, many evaluating the role of combination therapies, and at least three agents (simvastatin, imatinib and aviptadil) are undergoing proof of concept studies in…
View more
Author(s):
AA Kroon
,
PW de Leeuw
Added:
3 years ago
Hypertension is a common and serious problem that is the major cause of morbidity and mortality worldwide.1–3 Over 70 million people in the US are affected by high blood pressure (BP) that requires treatment, and nearly one-third of the adult population in the US have a BP of ≥140/90mmHg, which is the defined cut-off value for hypertension.2,4 It is estimated that over 44% of people in Europe are…
View more
Author(s):
Nazzareno Galiè
Added:
3 years ago
The field of pulmonary arterial hypertension (PAH) has recently been characterised by rapid improvements in therapeutic options and corresponding improvements in patient outcomes. In 1991, estimates from the US Department of Health and Human Services National Institutes of Health (NIH) Registry painted a grim portrait of survival in patients with pulmonary hypertension – then called primary…
View more
Author(s):
Nazzareno Galiè
Added:
3 years ago
The field of pulmonary arterial hypertension (PAH) has recently been characterised by rapid improvements in therapeutic options and corresponding improvements in patient outcomes. In 1991, estimates from the US Department of Health and Human Services National Institutes of Health (NIH) Registry painted a grim portrait of survival in patients with pulmonary hypertension - then called primary…
View more